海辰药业股价跌5%，富国基金旗下1只基金位居十大流通股东，持有70万股浮亏损失185.5万元

Group 1 - The core point of the article highlights that Haisun Pharmaceutical experienced a 5% drop in stock price, trading at 50.30 yuan per share, with a total market capitalization of 6.036 billion yuan as of the report date [1] - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's revenue composition is primarily from cardiovascular drugs (87.12%), followed by antibiotics (5.69%), active pharmaceutical ingredients and intermediates (1.68%), digestive drugs (1.50%), antiviral drugs (1.47%), and other categories [1] Group 2 - Among the top circulating shareholders of Haisun Pharmaceutical, the Fuguo Fund's Fuguo Steady Growth Mixed A (010624) fund entered the top ten in the third quarter, holding 700,000 shares, which is 0.85% of the circulating shares [2] - The Fuguo Steady Growth Mixed A fund has a total scale of 6.13 billion yuan, with a year-to-date return of 5.37% and a one-year return of 36.61% [2] - The fund manager, Fan Yan, has been in the position for 10 years and 88 days, with the fund's best return during this period being 187.76% and the worst being -15.11% [3]